• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Orally disintegrating Zyprexa appears to cause less weight gain

Orally disintegrating Zyprexa appears to cause less weight gain

May 1, 2008
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Dilip Jeste, MD

A few studies have shown that orally disintegrating Zyprexa Zydis appears to cause less weight gain than standard Zyprexa, but they have been short term stud- ies. This one-year study (which did not receive any industry funding) enrolled 26 patients, all of whom had schizophrenia or schizoaffective disorder, and all of whom had been stabilized on standard Zyprexa (average dose 13.9 mg/day). These patients ranged from overweight to obese, with an average BMI of 32.4, and an average weight of 96.2 kg (212 pounds). In this open trial, patients were switched to the equivalent dose of Zyprexa Zydis. Of the 22 patients who completed the trial, 82% lost weight, and the average weight loss at one year was 2.7 kg (5.9 pounds). Most of the weight loss occurred within the first three months (Chawl B and Luxton-Andrew H, Hum Psychopharmacol Clin Exp 2008;23:211-216).

TCPR’s Take: Because this was an open trial, some of this weight loss may have been due to the effects of expectancy rather than the effect of the change in formulation per se. Nonetheless, this represents the fifth study consistent with the theory that Zyprexa Zydis causes less weight gain than standard Zyprexa. Since Zydis disintegrates on contact with the tongue, much of it is absorbed in the blood- stream before reaching the stomach. If the Zyprexa causes weight gain by stimulat- ing serotonin receptors in the stomach, Zydis may decrease weight gain by avoid- ing this hypothetical mechanism of action.

General Psychiatry
KEYWORDS antidepressants
    www.thecarlatreport.com
    Issue Date: May 1, 2008
    SUBSCRIBE NOW
    Table Of Contents
    The MoCA: A Better MMSE?
    Tests to Detect Malingering
    Tamoxifen appears effective for mania
    Orally disintegrating Zyprexa appears to cause less weight gain
    A new study is consistent with FDA’s black box requirements for antidepressants.
    The Utility of Neuropsychological Testing
    DOWNLOAD NOW
    Featured Book
    • MFB7e_cover_sm.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • image.png
      General Psychiatry

      Four Natural Therapies for ADHD (with Richard Brown, MD)

      Richard Brown, MD, shows us how to use his top four natural therapies for ADHD: Pycnoginol, Rhodiola rosea, Racetams, American Ginseng.



      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.